These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Epidermal growth factor receptor blockers for the treatment of ovarian cancer. Morrison J; Thoma C; Goodall RJ; Lyons TJ; Gaitskell K; Wiggans AJ; Bryant A Cochrane Database Syst Rev; 2018 Oct; 10(10):CD007927. PubMed ID: 30321910 [TBL] [Abstract][Full Text] [Related]
10. Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy. Chan KK; Glenny AM; Weldon JC; Furness S; Worthington HV; Wakeford H Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD010341. PubMed ID: 26625332 [TBL] [Abstract][Full Text] [Related]
11. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer. Vasconcellos VF; Marta GN; da Silva EM; Gois AF; de Castria TB; Riera R Cochrane Database Syst Rev; 2020 Jan; 1(1):CD009256. PubMed ID: 31930743 [TBL] [Abstract][Full Text] [Related]
12. Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic review. Chen X; Liu Y; Røe OD; Qian Y; Guo R; Zhu L; Yin Y; Shu Y PLoS One; 2013; 8(3):e59314. PubMed ID: 23555654 [TBL] [Abstract][Full Text] [Related]
13. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Soria JC; Wu YL; Nakagawa K; Kim SW; Yang JJ; Ahn MJ; Wang J; Yang JC; Lu Y; Atagi S; Ponce S; Lee DH; Liu Y; Yoh K; Zhou JY; Shi X; Webster A; Jiang H; Mok TS Lancet Oncol; 2015 Aug; 16(8):990-8. PubMed ID: 26159065 [TBL] [Abstract][Full Text] [Related]
14. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence. Gridelli C; De Marinis F; Di Maio M; Cortinovis D; Cappuzzo F; Mok T Lung Cancer; 2011 Mar; 71(3):249-57. PubMed ID: 21216486 [TBL] [Abstract][Full Text] [Related]
15. Anti-epidermal growth factor receptor therapy for glioblastoma in adults. Lee A; Arasaratnam M; Chan DLH; Khasraw M; Howell VM; Wheeler H Cochrane Database Syst Rev; 2020 May; 5(5):CD013238. PubMed ID: 32395825 [TBL] [Abstract][Full Text] [Related]
16. Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations. Cheng Y; Murakami H; Yang PC; He J; Nakagawa K; Kang JH; Kim JH; Wang X; Enatsu S; Puri T; Orlando M; Yang JC J Clin Oncol; 2016 Sep; 34(27):3258-66. PubMed ID: 27507876 [TBL] [Abstract][Full Text] [Related]
17. Chemotherapy for advanced non-small cell lung cancer in the elderly population. Santos FN; Castria TB; Cruz MR; Riera R Sao Paulo Med J; 2016; 134(5):465-466. PubMed ID: 27901246 [TBL] [Abstract][Full Text] [Related]
18. Chemotherapy for advanced non-small cell lung cancer in the elderly population. Santos FN; de Castria TB; Cruz MR; Riera R Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD010463. PubMed ID: 26482542 [TBL] [Abstract][Full Text] [Related]
19. Trastuzumab-containing regimens for metastatic breast cancer. Balduzzi S; Mantarro S; Guarneri V; Tagliabue L; Pistotti V; Moja L; D'Amico R Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD006242. PubMed ID: 24919460 [TBL] [Abstract][Full Text] [Related]
20. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Wu YL; Cheng Y; Zhou X; Lee KH; Nakagawa K; Niho S; Tsuji F; Linke R; Rosell R; Corral J; Migliorino MR; Pluzanski A; Sbar EI; Wang T; White JL; Nadanaciva S; Sandin R; Mok TS Lancet Oncol; 2017 Nov; 18(11):1454-1466. PubMed ID: 28958502 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]